Three Questions with Sedgwick’s Jeremy Schutz

December 4, 2024Three Questions

Reading Time : 2 min

In this edition of Three Questions, health care & life sciences partner Nate Brown spoke with Jeremy Schutz, director of business development, recall & remediation at Sedgwick, to explore key strategies that pharmaceutical companies and medical device manufacturers can adopt to mitigate risks related to supply chain disruptions, cybersecurity threats and increased FDA enforcement of quality control and compliance.

Sedgwick is the world’s leading expert in product recall and remediation spanning over 7,000 recalls, in 100 countries, and 50 languages.

What operational strategies can pharmaceutical companies adopt to mitigate the risks of supply chain disruptions?

In 2024, supply chain disruptions continue to be a significant risk for pharmaceutical companies, especially in the context of global component and ingredient shortages and transportation challenges. Companies should adopt a risk-based approach by diversifying their supplier base, investing in domestic production and building stronger supplier relationships to improve resilience. Real-time supply chain monitoring through digital tools like blockchain can help companies track and predict potential bottlenecks. For 2025, stakeholders should watch for increased regulatory pressure from the FDA to ensure supply chain transparency and resilience, particularly for essential drugs and devices critical to patient health.

How can medical device manufacturers minimize the risk of cybersecurity threats?

With the FDA’s new and stricter cybersecurity regulations, medical device manufacturers face increased risks. Manufacturers must integrate cybersecurity protocols early in the product development process, ensuring compliance with FDA guidelines for cybersecurity risk management. This includes secure software development, regular updates, vulnerability monitoring and patch management. Manufacturers should also establish post-market cybersecurity monitoring programs. Looking ahead to 2025, the FDA is expected to intensify its focus on artificial intelligence (AI)-driven medical devices and cybersecurity for wearables, which will require manufacturers to maintain a proactive cybersecurity strategy to prevent costly disruptions and recalls.

How can life sciences companies mitigate the risks associated with increased FDA enforcement of quality control and compliance?

In 2024, the FDA has ramped up inspections and enforcement actions, especially related to quality control in manufacturing processes for both pharmaceuticals and medical devices. To mitigate risks, companies should implement continuous quality improvement (CQI) processes, ensuring that manufacturing standards meet Good Manufacturing Practices (GMP) and FDA regulations. This includes regular internal audits, employee training on compliance and investing in digital quality management systems (QMS) that provide real-time monitoring and documentation of production processes. As we approach 2025, companies should anticipate more FDA scrutiny on data integrity and digital record-keeping, making it essential to maintain robust data security and transparency throughout the product lifecycle.

Share This Insight

Previous Entries

Eye on FDA

September 24, 2025

On Tuesday, September 23, 2025, FDA published guidance titled “Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency.” The guidance, a draft of which was published on May 6, 2024, specifies the factors that FDA intends to assess in deciding whether to issue an enforcement discretion policy with regard to in vitro diagnostics (IVD) manufacturers offering unapproved IVDs, among other devices, during a declared emergency. These factors include:

...

Read More

Eye on FDA

September 23, 2025

Last week, the U.S. Food and Drug Administration (FDA) issued a proposed rule to revoke the color additive listing for Orange B, a synthetic dye historically used on the casings and surfaces of frankfurters and sausages. This action is part of the broader “Make America Healthy Again” (MAHA) initiative to phase out petroleum-based foods from the American food supply by the end of 2026 and efforts to modernize the agency’s regulations.

...

Read More

Eye on FDA

September 12, 2025

The White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., released its highly anticipated strategy outlining a multi-agency approach focused on addressing childhood chronic disease. The strategy builds on the Commission’s inaugural health assessment, a report which examined the rising rates of childhood chronic diseases in the country and identified four primary drivers: poor diet due to consumption of ultra-processed foods (UPFs), exposure to environmental chemicals; increased technological use; and overmedicalization. To combat these challenges, the strategy released on September 9, 2025, outlines a four-prong approach which provides further insight into the areas the administration sees as key areas of MAHA going forward: advancing research, realigning incentives, increasing public awareness and fostering private sector collaborations.

...

Read More

Eye on FDA

September 8, 2025

On September 3, 2025, the Food and Drug Administration (FDA) announced Rare Disease Evidence Principles (RDEP) with processes aimed at providing greater predictability and facilitating the development and review of drugs intended to treat rare diseases with very small patient populations and significant unmet medical needs driven by a known genetic defect. In conjunction with the agency’s announcement of the new processes jointly proposed by the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the agency also unveiled additional information regarding eligibility and the potential for post-marketing requirements for those sponsors who participate in it.

...

Read More

Eye on FDA

August 27, 2025

Food dye reform has been an area of focus for the Trump administration as part of its Make America Healthy Again (MAHA) initiative, giving momentum to an effort the Food and Drug Administration (FDA) had already started by banning Red No. 3 for use in food and ingested drugs. FDA has continued to prioritize this work by taking actions to phase out the use of synthetic dyes and move to natural dyes since calling for these changes earlier this year, as discussed in our previous blog on the related announcement by the administration.

...

Read More

Eye on FDA

August 12, 2025

Last week, former Food and Drug Administration (FDA) Commissioner David Kessler submitted a citizen petition urging FDA to revoke the generally recognized as safe (GRAS) status of refined carbohydrates used in industrial food processing. The petition follows FDA’s and the United States Department of Agriculture’s (USDA) joint request for information (RFI) to establish a formal definition for ultra-processed foods (UPFs) and offers FDA a legal pathway to change the regulatory status of these ingredients.

...

Read More

Eye on FDA

August 6, 2025

On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary. After an independent safety review of fluoropolymers in medical devices showed no conclusive evidence of health issues, FDA concluded that fluoropolymers are “very unlikely to cause toxicity” because of molecular size and further that they are essential for medical devices to function. As a result, “FDA’s evaluation is that currently there is no reason to restrict their continued use in devices.” This announcement will be a source of relief to the device and diagnostics industries.

...

Read More

Eye on FDA

July 25, 2025

On July 25, the U.S. Food and Drug Administration (FDA), in collaboration with the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA), unveiled the highly anticipated joint request for information on ultra-processed foods (UPFs). Specifically, the administration is seeking information and data to help develop a uniform definition for UPFs in the U.S. food supply.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.